These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 12132563

  • 1. Cost-effectiveness of gemifloxacin: results from the GLOBE study.
    Halpern MT, Palmer CS, Zodet M, Kirsch J.
    Am J Health Syst Pharm; 2002 Jul 15; 59(14):1357-65. PubMed ID: 12132563
    [Abstract] [Full Text] [Related]

  • 2. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes.
    Wilson R, Schentag JJ, Ball P, Mandell L, 068 Study Group.
    Clin Ther; 2002 Apr 15; 24(4):639-52. PubMed ID: 12017408
    [Abstract] [Full Text] [Related]

  • 3. Time course of recovery of health status following an infective exacerbation of chronic bronchitis.
    Spencer S, Jones PW, GLOBE Study Group.
    Thorax; 2003 Jul 15; 58(7):589-93. PubMed ID: 12832673
    [Abstract] [Full Text] [Related]

  • 4. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.
    Torrance G, Walker V, Grossman R, Mukherjee J, Vaughan D, La Forge J, Lampron N.
    Pharmacoeconomics; 1999 Nov 15; 16(5 Pt 1):499-520. PubMed ID: 10662396
    [Abstract] [Full Text] [Related]

  • 5. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.
    Grossman R, Mukherjee J, Vaughan D, Eastwood C, Cook R, LaForge J, Lampron N.
    Chest; 1998 Jan 15; 113(1):131-41. PubMed ID: 9440580
    [Abstract] [Full Text] [Related]

  • 6. Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.
    Jivcu C, Gotfried M.
    Int J Chron Obstruct Pulmon Dis; 2009 Jan 15; 4():291-300. PubMed ID: 19684863
    [Abstract] [Full Text] [Related]

  • 7. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group.
    File T, Schlemmer B, Garau J, Lode H, Lynch S, Young C.
    J Chemother; 2000 Aug 15; 12(4):314-25. PubMed ID: 10949981
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
    Sethi S, Fogarty C, Fulambarker A.
    Respir Med; 2004 Aug 15; 98(8):697-707. PubMed ID: 15303633
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
    Bhavnani SM, Ambrose PG.
    Diagn Microbiol Infect Dis; 2008 Jan 15; 60(1):59-64. PubMed ID: 17889491
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS.
    Int J Antimicrob Agents; 2004 Jun 15; 23(6):533-46. PubMed ID: 15194123
    [Abstract] [Full Text] [Related]

  • 11. Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials.
    Zhang L, Wang R, Falagas ME, Chen LA, Liu YN.
    Chin Med J (Engl); 2012 Feb 15; 125(4):687-95. PubMed ID: 22490497
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin.
    Ball P, Wilson R, Mandell L, Brown J, Henkel T, 069 Clinical Study Group.
    J Chemother; 2001 Jun 15; 13(3):288-98. PubMed ID: 11450888
    [Abstract] [Full Text] [Related]

  • 13. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis.
    Wilson R, Langan C, Ball P, Bateman K, Pypstra R, Gemifloxacin 207 Clinical Study Group.
    Respir Med; 2003 Mar 15; 97(3):242-9. PubMed ID: 12645831
    [Abstract] [Full Text] [Related]

  • 14. Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.
    File TM, Tillotson GS.
    Expert Rev Anti Infect Ther; 2004 Dec 15; 2(6):831-43. PubMed ID: 15566328
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections.
    Ball P, File TM, Twynholm M, Henkel T.
    Int J Antimicrob Agents; 2001 Jul 15; 18(1):19-27. PubMed ID: 11463522
    [Abstract] [Full Text] [Related]

  • 16. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis.
    Destache CJ, Dewan N, O'Donohue WJ, Campbell JC, Angelillo VA.
    J Antimicrob Chemother; 1999 Mar 15; 43 Suppl A():107-13. PubMed ID: 10225580
    [Abstract] [Full Text] [Related]

  • 17. Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization.
    Fogarty C, de Wet R, Mandell L, Chang J, Rangaraju M, Nusrat R.
    Chest; 2005 Oct 15; 128(4):1980-8. PubMed ID: 16236845
    [Abstract] [Full Text] [Related]

  • 18. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK, Triller DM, Yong CS, Lodise TP.
    Ann Pharmacother; 2004 Oct 15; 38(7-8):1226-35. PubMed ID: 15187209
    [Abstract] [Full Text] [Related]

  • 19. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin.
    Lipsky BA, Unowsky J, Zhang H, Townsend L, Talbot GH.
    Clin Ther; 1999 Jun 15; 21(6):954-65. PubMed ID: 10440620
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
    Dresser LD, Niederman MS, Paladino JA.
    Chest; 2001 May 15; 119(5):1439-48. PubMed ID: 11348951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.